Arnott I - Search Results

1

Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort.

Plevris N, Fulforth J, Siakavellas S, Robertson A, Hall R, Tyler A, Jenkinson PW, Campbell I, Chuah CS, Kane C, Veryan J, Lam WL, Saunders J, Kelly C, Gaya D, Jafferbhoy H, Macdonald JC, Seenan JP, Mowat C, Naismith G, Potts LF, Sutherland DI, Watts D, Arnott I, Bain G, Jones G, Lees CW. Plevris N, et al. Among authors: arnott i. J Gastroenterol Hepatol. 2021 Aug;36(8):2067-2075. doi: 10.1111/jgh.15390. Epub 2021 Mar 5. J Gastroenterol Hepatol. 2021. PMID: 33381875

2

The spectrum of ischaemic colitis.

Arnott ID, Ghosh S, Ferguson A. Arnott ID, et al. Eur J Gastroenterol Hepatol. 1999 Mar;11(3):295-303. doi: 10.1097/00042737-199903000-00014. Eur J Gastroenterol Hepatol. 1999. PMID: 10333203

3

Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: possible endothelial cell injury.

Arnott ID, Ghosh S. Arnott ID, et al. Eur J Gastroenterol Hepatol. 2000 May;12(5):569-73. doi: 10.1097/00042737-200012050-00016. Eur J Gastroenterol Hepatol. 2000. PMID: 10833103

4

Abnormal intestinal permeability predicts relapse in inactive Crohn disease.

Arnott ID, Kingstone K, Ghosh S. Arnott ID, et al. Scand J Gastroenterol. 2000 Nov;35(11):1163-9. doi: 10.1080/003655200750056637. Scand J Gastroenterol. 2000. PMID: 11145287

5

Gut luminal neutrophil migration is influenced by the anatomical site of Crohn's disease.

Arnott ID, Drummond HE, Ghosh S. Arnott ID, et al. Eur J Gastroenterol Hepatol. 2001 Mar;13(3):239-43. doi: 10.1097/00042737-200103000-00004. Eur J Gastroenterol Hepatol. 2001. PMID: 11293442

6

Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?

Arnott ID, Watts D, Ghosh S. Arnott ID, et al. Aliment Pharmacol Ther. 2002 May;16(5):857-67. doi: 10.1046/j.1365-2036.2002.01242.x. Aliment Pharmacol Ther. 2002. PMID: 11966492 Free article. Review.

7

Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety.

Arnott ID, Watts D, Satsangi J. Arnott ID, et al. Pharmacol Res. 2003 Jan;47(1):1-10. doi: 10.1016/s1043-6618(02)00264-5. Pharmacol Res. 2003. PMID: 12526855 Review.

8

Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis.

Ho GT, Nimmo ER, Tenesa A, Fennell J, Drummond H, Mowat C, Arnott ID, Satsangi J. Ho GT, et al. Gastroenterology. 2005 Feb;128(2):288-96. doi: 10.1053/j.gastro.2004.11.019. Gastroenterology. 2005. PMID: 15685540

9

The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease.

Noble CL, Nimmo ER, Drummond H, Ho GT, Tenesa A, Smith L, Anderson N, Arnott ID, Satsangi J. Noble CL, et al. Gastroenterology. 2005 Dec;129(6):1854-64. doi: 10.1053/j.gastro.2005.09.025. Gastroenterology. 2005. PMID: 16344054

10

Contribution of the NOD1/CARD4 insertion/deletion polymorphism +32656 to inflammatory bowel disease in Northern Europe.

Van Limbergen J, Russell RK, Nimmo ER, Törkvist L, Lees CW, Drummond HE, Smith L, Anderson NH, Gillett PM, McGrogan P, Hassan K, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Sjöqvist U, Lördal M, Farrington SM, Dunlop MG, Wilson DC, Satsangi J. Van Limbergen J, et al. Among authors: arnott id. Inflamm Bowel Dis. 2007 Jul;13(7):882-9. doi: 10.1002/ibd.20124. Inflamm Bowel Dis. 2007. PMID: 17285593

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

143 results

Search Page